Systematic review sharpens the evidence for NAC in dogs and cats

N-acetylcysteine has long been familiar to small-animal clinicians as the go-to antidote for acetaminophen exposure, but a new systematic review argues that its broader use in dogs and cats has outpaced the evidence. Writing in Frontiers in Veterinary Science, investigators from the University of Veterinary Medicine Budapest and collaborators reviewed the veterinary literature through August 1, 2026, and concluded that NAC's evidence base is strongest in feline acetaminophen toxicosis, while many other indications remain preliminary, indirect, or heavily extrapolated. (frontiersin.org)

The review arrives as NAC's role in companion-animal medicine has been expanding. It's used not only as an antidote, but also as a mucolytic, thiol donor, cytoprotective agent, and topical adjunct in settings ranging from respiratory disease to otitis and ocular surface disease. A separate 2026 narrative review in the Croatian Veterinary Journal similarly described growing interest in NAC's antioxidant, anti-inflammatory, and mucolytic roles, but emphasized that species-specific evidence is still limited. (hrcak.srce.hr)

Methodologically, the Frontiers team re-screened a 104-record legacy library and added 12 more eligible reports from updated searches, ending with 71 studies in the qualitative synthesis. The evidence was heavily skewed toward dogs, while feline clinical data were concentrated in acetaminophen toxicosis, pharmacokinetics, airway safety, and acute-on-chronic kidney disease. Publication dates spanned 1980 to 2026, and the authors repeatedly stress that many commonly cited dosing schedules come from expert synthesis and clinical tradition, not modern dose-ranging trials. (frontiersin.org)

The clearest takeaway is that acetaminophen toxicosis remains NAC's best-supported indication. In cats, controlled challenge studies showed reductions in methemoglobinemia, glutathione depletion, Heinz body formation, and mortality, particularly when treatment started early. In dogs, the evidence was smaller but still supportive, including experimental data showing altered acetaminophen disposition and case-based reports of recovery within multimodal treatment. Outside toxicology, though, the picture becomes much less certain. The review found limited or mixed evidence for hepatobiliary disease, respiratory use, neurologic protection, and cardiovascular applications, and noted that some settings, including perioperative neuroprotection and nebulized use in feline asthma, were neutral or unfavorable. (frontiersin.org)

One of the paper's most practical contributions is its focus on evidence maturity. The authors identify a handful of newer, more clinically relevant adjunctive areas, including parvoviral enteritis, feline acute-on-chronic kidney disease, canine babesiosis, and local antimicrobial applications, but stop short of calling any of them established. That caution is supported by the surrounding literature. Recent PubMed-indexed studies suggest NAC may improve oxidative stress markers and hematologic recovery in canine Babesia gibsoni infection, and in vitro studies have found antimicrobial or antifungal activity against pathogens associated with canine otitis externa, including Malassezia pachydermatis. Still, those findings don't yet equal proven patient-level benefit in routine practice. (frontiersin.org)

The review also underscores why species and route matter. In cats, the only crossover pharmacokinetic study of conventional aqueous NAC found low oral bioavailability, about 19.3%, and rapid elimination after both oral and IV dosing. No equivalent pharmacokinetic study was identified in dogs, which the authors describe as a consequential gap because canine dosing recommendations are widely repeated despite limited exposure-response data. Safety is another practical concern: oral NAC commonly causes nausea, salivation, or vomiting, and rapid IV administration can provoke non-IgE-mediated histamine release, hypotension, or bronchospasm. The paper cites a canine case report of severe collapse during an IV loading dose, and it flags nebulized NAC as problematic in asthmatic cats because it increased airway resistance in an experimental model. (frontiersin.org)

Why it matters: For veterinary professionals, this is less a story about a new drug than a recalibration of an old one. NAC still has a clear place in toxicology, and the mechanistic rationale for broader antioxidant or mucolytic use is easy to understand. But the review is a reminder to separate biologic plausibility from clinically proven benefit. In day-to-day medicine, that means being careful about presenting NAC as established therapy outside its best-supported indications, paying close attention to formulation and route, and recognizing that topical or adjunctive uses in ears, eyes, liver disease, or critical illness may be reasonable in some cases without yet being strongly evidence-backed. (frontiersin.org)

What to watch: The authors call for controlled clinical trials, population pharmacokinetic work in dogs, and disease-specific studies that move beyond biomarkers to patient outcomes. If those studies arrive, the most likely near-term growth areas appear to be antimicrobial-adjunct use in otitis and keratitis, and supportive use in oxidative-stress-heavy conditions such as babesiosis, parvoviral enteritis, or kidney injury, but for now, NAC's move from antidote to true multimodal adjunct is still incomplete. (frontiersin.org)